Abstract
BACKGROUND: Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. METHODS: We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. RESULTS: A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 percent, P
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2091-2098 |
| Number of pages | 8 |
| Journal | New England Journal of Medicine |
| Volume | 349 |
| Issue number | 22 |
| DOIs | |
| State | Published - Nov 27 2003 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. / Forastiere, Arlene A.; Goepfert, Helmuth; Maor, Moshe; Pajak, Thomas F.; Weber, Randal; Morrison, William; Glisson, Bonnie; Trotti, Andy; Ridge, John A.; Chao, Clifford; Peters, Glen; Lee, Ding Jen; Leaf, Andrea; Ensley, John; Cooper, Jay.
In: New England Journal of Medicine, Vol. 349, No. 22, 27.11.2003, p. 2091-2098.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer
AU - Forastiere, Arlene A.
AU - Goepfert, Helmuth
AU - Maor, Moshe
AU - Pajak, Thomas F.
AU - Weber, Randal
AU - Morrison, William
AU - Glisson, Bonnie
AU - Trotti, Andy
AU - Ridge, John A.
AU - Chao, Clifford
AU - Peters, Glen
AU - Lee, Ding Jen
AU - Leaf, Andrea
AU - Ensley, John
AU - Cooper, Jay
PY - 2003/11/27
Y1 - 2003/11/27
N2 - BACKGROUND: Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. METHODS: We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. RESULTS: A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 percent, P
AB - BACKGROUND: Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. METHODS: We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. RESULTS: A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 percent, P
UR - http://www.scopus.com/inward/record.url?scp=0345714860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345714860&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa031317
DO - 10.1056/NEJMoa031317
M3 - Article
VL - 349
SP - 2091
EP - 2098
JO - New England Journal of Medicine
JF - New England Journal of Medicine
SN - 0028-4793
IS - 22
ER -